Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05713721
Other study ID # MJFF-022062
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2023
Est. completion date December 31, 2024

Study information

Verified date June 2023
Source University Hospital Schleswig-Holstein
Contact Anne Weissbach, MD
Phone +49 451 3101 8219
Email anne.weissbach@neuro.uni-luebeck.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Hereditary Parkinson and dystonia syndromes are rare, as are people who carry the predisposition for Parkinson or dystonia but do not have symptoms. It is particularly important to study these people because they are a good model for understanding the development of common non-hereditary Parkinson's and dystonia. To do this, the investigators want to look at how the brain works and how different areas of the brain communicate with each other. The investigators want to identify differences in brain regions connecting perception and action between mutation carriers that develop clinical symptoms and those who stay healthy in different subgroups of inherited Parkinson-dystonia syndromes. Mutation carriers with and without symptoms of three different inherited Parkinson-dystonia syndromes will be investigated at their homes with the help of a mobile examination unit. To detect even subtle signs, which the mutation carriers might not even be aware of, the investigators will use a detailed video-based and -documented movement examination and a non-invasive magnetic stimulation technique that investigates how a sensory, i.e., electrical stimulus can influence the motor response in a hand muscle. Our study will allow the investigators, on the one hand, to define specific markers that protect some mutation carriers from having clinical symptoms and, on the other hand, to identify neurophysiological characteristics that all mutation carriers share whether or not they have clinical symptoms. These are important information for a better understanding of the basis of these disorders and for the development of new treatment strategies, which can also be transferred to genetically-undefined Parkinson's and dystonia syndromes. Through this study, large groups of mutation carriers that have received an in-depth clinical and neurophysiological examination and can be investigated longitudinally in future studies will be build up.


Description:

Monogenic Parkinson-dystonia syndromes are rare but very valuable model disorders for genetically undefined syndromes, as their genetic cause, i.e., pathogenic gene variants, have been identified. For certain subtypes, even the neuroanatomical basis was discovered. Despite the different genetic and anatomical characteristics, a strong clinical overlap was reported between PARK-Parkin/PARK-PINK1, DYT/PARK-GCH1, and DYT/PARK-TAF1. Interestingly, previous research in these different Parkinson-dystonia syndromes suggests a distinct pattern of neurophysiological alterations within the primary motor and premotor-motor network for each syndrome. Even asymptomatic, heterozygous mutation carriers, show abnormalities within neurophysiological and in addition, functional, metabolic, and structural imaging studies. In general, a better clinical and neurophysiological evaluation of asymptomatic compared to symptomatic mutation carriers and healthy controls across subgroups is warranted. However, the number of mutation carriers per subgroup is limited and some are unable to travel to Lübeck to participate in research. To increase the participant size, in addition to the examination in our neurophysiological laboratory, the investigators want to visit and investigate some mutation carriers in their home environment with a mobile examination unit. In this regard, the transcranial magnetic stimulation paradigm of short-latency afferent inhibition (SAI) is of great interest as it can reliably capture the effects of sensory input (median nerve stimulation) on motor output (MEP amplitude) without complex neuronavigation. Additionally, a video-based clinical examination will be performed, which will be rated offline in a blinded fashion by movement disorder specialists to correlate SAI with symptom severity. Therefore, the proposed project will, for the first time, allow a direct comparison of sensorimotor integration deficits in correlation to clinical signs between three different monogenic Parkinson-dystonia syndromes. Furthermore, contrasting the findings between asymptomatic and symptomatic mutation carriers will help, on the one hand, to draw conclusions on potential protective markers, and on the other hand, to identify neurophysiological endophenotypes. Furthermore, successful completion of the project will generate clinically well-defined monogenic subgroups with particular sensorimotor abnormalities, who can serve as model disorders in further research projects that aim to characterize sensorimotor deficit in a cognitive framework and in a longitudinal fashion.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 31, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion criteria for mutation carriers: - Pathogenic Parkin, PINK1, GCH1, or TAF1 gene variant - Age >18 years - Informed consent Inclusion criteria for healthy control participants: - No movement disorder - Age >18 years - Informed consent - No medication with influences on the central nervous system Exclusion Criteria: - Age <18 years - Pregnancy - Epilepsy - Medication that reduces the seizure threshold

Study Design


Intervention

Device:
Transcranial magnetic stimulation (TMS)
TMS over the left primary motor cortex will be performed. To investigate sensorimotor integration, an electrical stimulus on the right index finger will precede the TMS pulse.
Other:
Video-based clinical examination
A standardized neurological examination will be performed and video taped. The videos will be rated by movement disorder specialists, wo are blinded for the symptom and mutation status of the participants.
24 hours drug withdrawal of dopaminergic medication
Examinations will be done under chronic dopaminergic treatment and after a 24 hours dopaminergic drug withdrawal.
Evaluation of deep brain stimulation
Examinations will be done before and after implantation of deep brain stimulation (clinically optimal stimulation vs. switched off stimulation)

Locations

Country Name City State
Germany Institute of Systems Motor Science Lübeck Lübeck Schleswig-Holstein

Sponsors (2)

Lead Sponsor Collaborator
University Hospital Schleswig-Holstein Michael J. Fox Foundation for Parkinson's Research

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Contrast sensorimotor integration in patients with three different monogenic Parkinson-dystonia syndromes. Transcranial magnetic stimulation (short-latency afferent inhibition) Two timepoints (if applicable): With chronic dopaminergic medication vs. 24h drug withdrawal OR before and after deep brain stimulation implantation
Primary Define whether asymptomatic mutation carriers show abnormalities in sensorimotor integration and clinical signs of Parkinson and dystonia upon video examination. Video based clinical examination One timepoint
Primary Correlate clinical symptom severity with changes in sensorimotor integration. Transcranial magnetic stimulation (short-latency afferent inhibition) and Video based clinical examination Two timepoints (patients) or one timepoint (asymptomatic mutation carriers and healthy control participants)
Primary Evaluate treatment effects on sensorimotor integration, e.g., for PARK-Parkin/PARK-PINK1 and DYT/PARK-GCH1 chronic dopaminergic medication and for DYT/PARK-TAF1 deep brain stimulation effects. Transcranial magnetic stimulation (short-latency afferent inhibition) Two timepoints (if applicable): With chronic dopaminergic medication vs. 24h drug withdrawal OR before and after deep brain stimulation implantation
See also
  Status Clinical Trial Phase
Completed NCT01433757 - Ampicillin for DYT-1 Dystonia Motor Symptoms Phase 1
Recruiting NCT00971854 - Alteration of Deep Brain Stimulation Parameters for Dystonia N/A
Enrolling by invitation NCT00355927 - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. N/A
Completed NCT00169338 - Pallidal Stimulation in Patients With Post-anoxic and Idiopathic Dystonia Phase 2
Completed NCT00004421 - Deep Brain Stimulation in Treating Patients With Dystonia Phase 2/Phase 3
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Recruiting NCT02583074 - Clinical Trial of STN-DBS for Primary Cranial-Cervical Dystonia N/A
Recruiting NCT06117020 - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals Phase 1
Completed NCT01432899 - Studying Childhood-Onset Hemidystonia
Completed NCT04948684 - Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism
Completed NCT05106816 - The Effects of Vibrotactile Stimulation in Patients With Movement Disorders N/A
Recruiting NCT05027997 - Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm Phase 2
Completed NCT00465790 - Research of Biomarkers in Parkinson Disease Phase 0
Active, not recruiting NCT00142259 - Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Phase 4
Recruiting NCT05663840 - Effects of Exercise on Dystonia Pathophysiology N/A
Not yet recruiting NCT06038097 - Efficacy and Safety of Radiofrequency Pallidotomy in the Management of Dystonia N/A
Recruiting NCT04286308 - Cortical-Basal Ganglia Speech Networks N/A
Active, not recruiting NCT03582891 - The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy N/A
Completed NCT03318120 - Exercise Training in Dystonia N/A
Completed NCT04568681 - Deep Brain Stimulation Effects in Dystonia